FIELD: pharmaceutics.
SUBSTANCE: described is aqueous composition for instillation in urinary bladder based on hyaluronic acid and chondroitin sulphate. Composition also contains mannitol or sorbitol in relation to sum of hyaluronic acid and chondroitin sulphate, equal to 0.014-4.2. Said composition can additionally contain zinc chloride.
EFFECT: invention provides high protective effect on urothelium cells after oxidative stress and increased mediated antimicrobial action due to inclusion of mannitol or sorbitol in composition, high direct antimicrobial action and protection of urothelium due to inclusion of zinc chloride, as well as controlled viscosity due to inclusion of mannitol and zinc chloride.
1 cl, 4 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR TREATMENT AND PREVENTION OF CYSTITIS | 2020 |
|
RU2751649C1 |
| COMPOSITION FOR INSTILLATION OF URINARY BLADDER WITH INCREASED STABILITY DURING STORAGE, CONTAINING CHONDROITIN SULPHATE (4_5 MG/ML), HYALURONIC ACID (16 MG/ML) AND PHOSPHATE BUFFER (PH 6_1-7_9), FOR TREATING CYSTITIS | 2018 |
|
RU2742277C1 |
| BLADDER INSULATION COMPOSITION CONTAINING CHONDROITIN SULPHATE (20 MG/ML), HYALURONIC ACID (16 MG/ML) AND PHOSPHATE BUFFER (pH 6.1-7.9), WITH INCREASED STORAGE STABILITY FOR CYSTITIS TREATMENT | 2018 |
|
RU2745869C1 |
| METHOD OF TREATING CYSTITIS | 2013 |
|
RU2537031C2 |
| COMPOSITION FOR TREATING CYSTITIS | 2013 |
|
RU2519010C1 |
| AGENT FOR TREATING CHRONIC INFLAMMATORY DISEASES OF URETHRA AND BLADDER | 2015 |
|
RU2602954C1 |
| METHOD OF TREATING INTERSTITIAL CYSTITIS USING MEDICINAL COMPOSITIONS | 2023 |
|
RU2824705C1 |
| INTEGRATED METHOD OF TREATING FEMALE PATIENTS SUFFERING FROM CHRONIC RECURRENT CYSTITIS AND REFRACTORY OVERACTIVE BLADDER | 2013 |
|
RU2550968C1 |
| METHOD OF TREATING CHRONIC CYSTITIS IN CHILDREN | 2013 |
|
RU2524769C1 |
| METHOD OF TREATING AND PREVENTING URINATION DISORDERS | 2019 |
|
RU2708524C1 |
